Dual Bispecific Regimen Shows Early Prostate Cancer Activity

Recovered source-gap item: Johnson & Johnson disclosed November 9 Phase 1 activity for pasritamig plus JNJ-9401 in metastatic castration-resistant prostate cancer. At the recommended regimen, 11 of 15 patients achieved a PSA decline of…




